Fibrates in the metabolic syndrome and in diabetes

Endocrinology and Metabolism Clinics of North America

Volumn 33, Issue 3, 2004, Pages 545-555

  Steiner, George ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CERIVASTATIN; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; SIMVASTATIN;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; GENETIC ANALYSIS; HEMOCONCENTRATION; HUMAN; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; METHODOLOGY; PATIENT; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL; TOXICITY;

CHOLINERGIC ANTAGONISTS; DIABETES MELLITUS, TYPE 2; HUMANS; METABOLIC SYNDROME X;

EID: 3242695837     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ecl.2004.04.002     Document Type: Review

References (35)

1. Anonymous. UK Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM. Diabetes Care. 20:1997;1683-1687
2. Gray R.S., Robbins D.C., Wang W., Yeh J.L., Fabsitz R.R., Cowan L.D., et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians: the Strong Heart Study. Atheroscler Thromb Vasc Biol. 17:1997;2713-2720
3. Alberti K.G.M.M., Zimmet P.Z., for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabet Med. 15:1998;539-553
4. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497
5. Barter P. Is high-density lipoprotein the protector of the cardiovascular system? Eur Heart J. 6:(Suppl A):2004;A19-A22
6. Assmann G., Schulte H. Relation of high density lipoprotein cholesterol and triglycerides to the incidence of atherosclerotic coronary artery disease. Prospective Cardiovascular Munster study. Am J Cardiol. 70:1992;733-737
7. Knopp R.H. Drug treatment of lipid disorders. N Engl J Med. 341:1999;498-511
8. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 30:2002;1280-1287
9. Staels B., Dallongeville J., Auwerx J., Schoonjans K., Leitersdorf E., Fruchart J.-C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093
10. Vu-Dac N., Gervois P., Jakel H., Nowak M., Bauge E., Dehondt H., et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators. J Biol Chem. 278:2003;17982-17985
11. Fruchart J.C. Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol. 88:2001;24N-29N
12. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 231:1975;360-381
13. Committee of Principal Investigators. A cooperative trial in the prevention of ischemic heart disease using clofibrate. Br Heart J. 40:1978;1069-1118
14. Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet. ii:1980;379-385
15. Committee of Principal Investigators. W.H.O. cooperative trial on primary prevention of ischemic heart disease using clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. ii:1984;600-604
16. Research Committee of the Scottish Society of Physicians. Ischemic heart disease: a secondary prevention trial using clofibrate. BMJ. 4:1971;775-784
17. Group of Physicians of the Newcastle upon Tyne Region. Trial of clofibrate in the treatment of ischemic heart disease. BMJ. 4:1971;767-775
18. Dewar H.A., Oliver M.F. Secondary prevention trials using clofibrate: a joint commentary on the Newcastle and Scottish trials. BMJ. 4:1971;784-786
19. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., et al. The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 317:1987;1237-1245
20. The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study. Circulation. 102:2000;21-27
21. Ericsson C.G., Hamsten A., Nilsson J., Grip L., de Faire U. Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 347:1996;849-853
22. Rubins H.B., Robins S.J., Collins D., Fye C.L., Anderson J.W., Elam M.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 341:1999;410-418
23. Rubins H.B., Robins S.J., Collins D., Nelson D.B., Elam M.B., Schaefer E.J., et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med. 162:2002;2597-2604
24. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., et al. Prevention of angiographic progression of coronary vein-graft by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) study group. Circulation. 96:1997;2137-2143
25. Koskinen P., Manttari M., Manninen V., Huttunen J.K., Heinonen O.P., Frick M.H. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 15:1992;820-825
26. Elkeles R.S., Diamond J.R., Poulter C., Dhanjil S., Nicolaides A.N., Mahmood S., et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care. 21:1998;641-648
27. Anonymous. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. [published erratum appears in Lancet 2001;357:1890] Lancet. 357:2001;905-910
28. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 104:2001;3046-3051
29. Vakkilainen J., Steiner G., Ansquer J.-C., Aubin F., Rattier S., Foucher C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins and progression of coronary artery disease. The Diabetes Atherosclerosis Intervention Study (DAIS). Circulation. 107:2003;1733-1737
30. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., et al., VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 285:2001;1585-1591
31. Steiner G. The use of fibrates and of statins in preventing atherosclerosis in diabetes. Curr Opin Lipidol. 12:2001;611-617
32. Neil A., Wheeler F., Cull C., Manley S., Keenan J., Holman R. Combination statin and fibrate therapy in type 2 diabetes from the Lipids in Diabetes Study. Diabetes. 52:(Suppl 1):2003;A74
33. Kyrklund C., Backman J.T., Neuvonen M., Neuvonen P.J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther. 73:2003;538-544
34. Backman J.T., Kyrklund C., Neuvonen M., Neuvonen P.J. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 72:2002;685-691
35. Kyrklund C., Backman J.T., Kivisto K.T., Neuvonen M., Laitila J., Neuvonen P.J. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 69:2001;340-345